The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | 11,813 |
| Stock-based compensation | 4,850 |
| Depreciation and amortization | 974 |
| Amortization of right-of-use assets | 309 |
| Provision for credit losses | 202 |
| Loss on disposal and impairment of assets | -210 |
| Loss (gain) on extinguishment of debt | -477 |
| Change in fair value of derivative liabilities | -8,107 |
| Gain on sale of patents | 5,375 |
| Amortization of debt issuance and debt discounts | 1,461 |
| Write-off of inventory related to pace disposal | 498 |
| Gain on lease modification | 7 |
| Accrued interest and accrued interest, related parties | 0 |
| Proceeds from tenant improvement funds | 586 |
| Accounts receivable | 2,296 |
| Inventory | 2,283 |
| Prepaid expenses and other assets | 724 |
| Accounts payable | -521 |
| Accrued expenses and contract liabilities | 1,965 |
| Operating leases | 156 |
| Net cash provided by operating activities | 3,876 |
| Purchases of property and equipment | 1,942 |
| Proceeds from sale of patents | 5,375 |
| Net cash provided by (used in) investing activities | 3,433 |
| Repayment of principal secured term loan | 1,438 |
| Proceeds from secured term loan | 23,000 |
| Proceeds from secured revolving credit facility | 655 |
| Payment of debt issuance costs | 371 |
| Proceeds from exercises of stock options | 556 |
| Payment of note payable | 27,747 |
| Proceeds from convertible promissory notes/secured promissory notes payable, related party-Nonrelated Party | 0 |
| Proceeds from convertible promissory notes/secured promissory notes payable, related party-Related Party | 0 |
| Payments to secured promissory notes payable, related party-Related Party | 0 |
| Proceeds from sale of common stock | 0 |
| Payments to factoring | 0 |
| Principal payments on finance leases | 242 |
| Net cash flows provided by financing activities | -5,587 |
| Effect of exchange rates on cash and cash equivalents | 0 |
| Net change in cash and cash equivalents during period | 1,722 |
| Cash and cash equivalents at beginning of period | 10,237 |
| Cash and cash equivalents at end of period | 11,959 |
SANUWAVE Health, Inc. (SNWV)
SANUWAVE Health, Inc. (SNWV)